May Hill Capital LLC increased its holdings in Novo Nordisk A/S (NYSE:NVO – Free Report) by 188.1% in the fourth quarter, HoldingsChannel.com reports. The fund owned 24,212 shares of the company’s stock after acquiring an additional 15,808 shares during the period. May Hill Capital LLC’s holdings in Novo Nordisk A/S were worth $1,232,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in NVO. Guerra Advisors Inc purchased a new stake in Novo Nordisk A/S in the third quarter worth $25,000. WealthCollab LLC lifted its stake in Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after acquiring an additional 260 shares during the period. American National Bank & Trust purchased a new stake in Novo Nordisk A/S in the fourth quarter worth $28,000. Maseco LLP bought a new position in Novo Nordisk A/S in the fourth quarter worth $29,000. Finally, Jackson Grant Investment Advisers Inc. bought a new position in Novo Nordisk A/S in the fourth quarter worth $29,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.
Novo Nordisk A/S Price Performance
Shares of NYSE:NVO opened at $44.71 on Friday. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $81.44. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The business has a fifty day moving average price of $39.73 and a 200-day moving average price of $46.69. The company has a market capitalization of $199.63 billion, a PE ratio of 10.50, a PEG ratio of 3.98 and a beta of 0.77.
Analyst Ratings Changes
NVO has been the subject of a number of research reports. The Goldman Sachs Group reiterated a “neutral” rating and issued a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. Morgan Stanley upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price objective for the company in a report on Tuesday, March 3rd. Kepler Capital Markets downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday, February 24th. Finally, Sanford C. Bernstein initiated coverage on Novo Nordisk A/S in a report on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $65.56.
Check Out Our Latest Report on NVO
Key Stories Impacting Novo Nordisk A/S
Here are the key news stories impacting Novo Nordisk A/S this week:
- Positive Sentiment: Novo Nordisk reported encouraging early data for its oral Wegovy program, with trial results highlighting meaningful weight-loss efficacy and better tolerability, reinforcing confidence in the company’s GLP-1 pipeline. Article Title
- Positive Sentiment: The company’s recent Q1 results beat estimates and it raised its 2026 outlook, suggesting the core business remains resilient despite a tougher competitive environment. Article Title
- Positive Sentiment: Investor commentary is increasingly focused on Novo Nordisk’s restructuring efforts, oral Ozempic/Wegovy launches, and telehealth partnerships, which are being viewed as potential growth drivers. Article Title
- Positive Sentiment: Hims & Hers noted a Novo Nordisk GLP-1 partnership as part of its weight-loss care expansion, underscoring broader commercial adoption of Novo’s obesity treatments. Article Title
- Neutral Sentiment: Several articles discussed Novo Nordisk’s valuation, long-term returns, and stock forecasts, but these were mostly commentary pieces rather than new fundamental developments. Article Title
- Neutral Sentiment: There was also a disclosure about gifted share transactions linked to CFO associates, which appears administrative rather than a major operating issue. Article Title
- Negative Sentiment: Market commentary continues to emphasize competitive pressure from Eli Lilly’s expanding GLP-1 portfolio, raising concerns about Novo Nordisk’s ability to defend its obesity market leadership. Article Title
- Negative Sentiment: One analyst-style piece explicitly argued against upgrading the stock, reflecting skepticism that the recent rebound has fully resolved the company’s longer-term challenges. Article Title
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.
The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.
Featured Stories
- Five stocks we like better than Novo Nordisk A/S
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
